Ascendia

  MARKET NEWS

Centogene Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort
NodThera is First to Demonstrate Reduction in Neuroinflammation in the Clinic With Brain Penetrant NLRP3 Inflammasome Inhibitor
Ocean Biomedical’s mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential to Address Global & Emerging US Malaria Challenges
Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
Purple Biotech Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients

  FEATURED EDITORIAL

  COMPANY PROFILE

With over 75 years of proven experience, Aptar Pharma is the go-to drug delivery expert, from formulation to patient, for pharma customers worldwide, providing innovative drug delivery systems, components, and active material solutions across the widest range of delivery routes, including nasal, pulmonary, ophthalmic, dermal, and injectables. Aptar Pharma Services provides early-stage to commercialization support to accelerate and de-risk the development journey. With a strong focus on innovation, Aptar Digital Health is a leading provider of integrated digital health solutions to enhance patient experiences across their treatment journey. With a global manufacturing footprint of 14 manufacturing sites, Aptar Pharma provides security of supply and local support to customers. Aptar Pharma is part of AptarGroup, Inc. Click here for more.

CLICK IMAGE FOR THIS WEEK’S FEATURED VIDEO

  EXCLUSIVE ONLINE CONTENT

Bora Pharmaceuticals Unveils Eye-Opening New Facility for Ophthalmic Manufacturing

Bora Pharmaceuticals Unveils Eye-Opening New Facility for Ophthalmic Manufacturing

Bora Pharmaceuticals recently announce the opening of a new state-of-the-art facility in Taoyuan City, Taiwan.  Officially opened by Bora Pharmaceuticals CEO Bobby Sheng and President of….

George Medicines Completes Recruitment of first Phase 3 Hypertension Trial Investigating Novel Single-Pill Triple Combination Candidate

George Medicines Completes Recruitment of first Phase 3 Hypertension Trial Investigating Novel Single-Pill Triple Combination Candidate

George Medicines recently announced all patients have been enrolled in its Phase 3 active-controlled trial evaluating the efficacy and safety of GMRx2, the company’s….

Gerresheimer Launches Open Innovation Program for the Development of Home Therapy Solutions

Gerresheimer Launches Open Innovation Program for the Development of Home Therapy Solutions

As an innovative system and solution provider, Gerresheimer is the global partner for the pharma and biotech industry. In collaboration with ekipa, a leading incubator for open innovation, Gerresheimer is calling on start-ups, companies, students, researchers, and….

Kindeva, Chiesi Group & H&T Presspart Announce Strategic Partnership for Dose Counter Technology Production

Kindeva, Chiesi Group & H&T Presspart Announce Strategic Partnership for Dose Counter Technology Production

Kindeva Drug Delivery and H&T Presspart are partnering with Chiesi Group for the installation of a production line for dose counter (DC) and dose indicator (DI) devices. Combining the specific….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER -  Long-Acting Injectable Nanoparticle Formulations

WHITEPAPER - Long-Acting Injectable Nanoparticle Formulations

Long acting injectable (LAI) formulations have been the subject of continued interest in the recent past due, in part, to their longer systemic circulation requiring less frequent dosing of drugs. Less frequent administration, as illustrated in Figure 1, make LAIs …

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

WHITEPAPER - Overcoming the Knowledge Gap: Long-Acting Injectables & Implantables

What’s In This Whitepaper?

Long-acting products, such as Long-Acting Injectables (LAIs) and implantables, have gained significant traction in recent years, revolutionizing patient treatment and medication adherence. By reducing the number of doses required, long-acting products improve patient compliance and eliminate …

WHITEPAPER - PLGA Nanoparticles - Bridging the Gap From R&D to GMP

WHITEPAPER - PLGA Nanoparticles - Bridging the Gap From R&D to GMP

Poly(lactic-co-glycolic acid) (PLGA) has emerged as a promising material for drug delivery and biomedical applications. Its exceptional biocompatibility, customizable degradation and release properties, and versatility have led to its approval by regulatory bodies like the FDA and EMA.…

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

 

Solubility of the active pharmaceutical ingredient (API) in an oral formulation is critical for absorption from the gastrointestinal (GI) tract and the intended therapeutic effect. Ensuring that an API has the necessary solubility can be challenging for drug developers …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

August 9 – Injection Devices
August 16 – Lyophilization Manufacturing